Commenting on the future plans of the company, Dr Chen says, "We strongly believe that the role of genomics and pharmacogenomics in the development of personalized medicines of the future is unarguably indispensable. Towards this trend, we at Vita Genomics and Shanghai GeneCore provide pharmacogenomic services and diagnostic tests that cater to the local needs of disease prevention and individualized therapy. Through our dynamic marketing arm, ACTS Biosciences, we hope to expand our services and products to clients not only in the Asia Pacific region but also around the globe."

On receiving the BioSpectrum Asia Pacific Emerging Company of the Year 2010 Award, Dr Ellson says, "I sincerely appreciate BioSpectrum and the reviewers for picking us for this award. It is a great endorsement justifying our nine-year long efforts by many hard-working people and it would certainly enhance team morale and comfort our investors."